Bridged ring NK1 antagonists
US7354922B2 · kind B2 · utility
3Cited by
4References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2005 |
| Grant date | Apr 8, 2008 |
| Priority date | — |
| Expiry date | Dec 1, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound having the general structure shown in Formula (I):or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.